| Dr Christopher G Baalmann, MD | |
|
9300 E 29th St N Ste 206, Wichita, KS 67226-2183 | |
| (316) 260-6763 | |
| Not Available |
| Full Name | Dr Christopher G Baalmann |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 13 Years |
| Location | 9300 E 29th St N Ste 206, Wichita, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992099113 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wesley Medical Center | Wichita, KS | Hospital |
| William Newton Hospital | Winfield, KS | Hospital |
| Coffey County Hospital | Burlington, KS | Hospital |
| Hospital District #6 Patterson Health Center | Anthony, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wichita Radiological Group Prof Assoc | 6507762960 | 27 |
News Archive
Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received a decision from the German regulatory agency (the Paul Ehrlich Institute, or PEI) under which the Company's Phase III clinical trial will be able to proceed in Germany after the Company makes three modifications, none of which affect the body of the trial or the bases for seeking product approval.
Alpha II, a leader in healthcare coding, compliance and reimbursement, announced today a new integration contract with Allscripts, the leading provider of clinical software, information and connectivity solutions for physicians. Alpha II's ClaimStaker software will soon be offered as an integrated solution to the Allscripts client base currently using MyWay, Tiger PM and Vision PM. Alpha II's CodeWizard will also be integrated into the Allscripts MyWay application. Estimated date of completion for the integrations is Q1 2011 for MyWay and Tiger, and Q2 2011 for integration into Vision.
A Michigan State University breast cancer researcher has shown that effective treatment options can be predicted based on the way certain breast cancer genes act or express themselves.
Patients treated for primary choroidal or ciliary body melanoma may not always benefit from an aggressive surveillance strategy for the detection of metastatic disease, caution US researchers.
Proteins are the building blocks of life and play a key role in all biological processes. Understanding how they interact with their environment is therefore vital to developing effective therapeutics and the foundation for designing artificial cells.
› Verified 4 days ago
| Entity Name | Wichita Radiological Group Prof Assoc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144256447 PECOS PAC ID: 6507762960 Enrollment ID: O20031208001045 |
News Archive
Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received a decision from the German regulatory agency (the Paul Ehrlich Institute, or PEI) under which the Company's Phase III clinical trial will be able to proceed in Germany after the Company makes three modifications, none of which affect the body of the trial or the bases for seeking product approval.
Alpha II, a leader in healthcare coding, compliance and reimbursement, announced today a new integration contract with Allscripts, the leading provider of clinical software, information and connectivity solutions for physicians. Alpha II's ClaimStaker software will soon be offered as an integrated solution to the Allscripts client base currently using MyWay, Tiger PM and Vision PM. Alpha II's CodeWizard will also be integrated into the Allscripts MyWay application. Estimated date of completion for the integrations is Q1 2011 for MyWay and Tiger, and Q2 2011 for integration into Vision.
A Michigan State University breast cancer researcher has shown that effective treatment options can be predicted based on the way certain breast cancer genes act or express themselves.
Patients treated for primary choroidal or ciliary body melanoma may not always benefit from an aggressive surveillance strategy for the detection of metastatic disease, caution US researchers.
Proteins are the building blocks of life and play a key role in all biological processes. Understanding how they interact with their environment is therefore vital to developing effective therapeutics and the foundation for designing artificial cells.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher G Baalmann, MD 9300 E 29th St N Ste 206, Wichita, KS 67226-2183 Ph: (316) 260-6763 | Dr Christopher G Baalmann, MD 9300 E 29th St N Ste 206, Wichita, KS 67226-2183 Ph: (316) 260-6763 |
News Archive
Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received a decision from the German regulatory agency (the Paul Ehrlich Institute, or PEI) under which the Company's Phase III clinical trial will be able to proceed in Germany after the Company makes three modifications, none of which affect the body of the trial or the bases for seeking product approval.
Alpha II, a leader in healthcare coding, compliance and reimbursement, announced today a new integration contract with Allscripts, the leading provider of clinical software, information and connectivity solutions for physicians. Alpha II's ClaimStaker software will soon be offered as an integrated solution to the Allscripts client base currently using MyWay, Tiger PM and Vision PM. Alpha II's CodeWizard will also be integrated into the Allscripts MyWay application. Estimated date of completion for the integrations is Q1 2011 for MyWay and Tiger, and Q2 2011 for integration into Vision.
A Michigan State University breast cancer researcher has shown that effective treatment options can be predicted based on the way certain breast cancer genes act or express themselves.
Patients treated for primary choroidal or ciliary body melanoma may not always benefit from an aggressive surveillance strategy for the detection of metastatic disease, caution US researchers.
Proteins are the building blocks of life and play a key role in all biological processes. Understanding how they interact with their environment is therefore vital to developing effective therapeutics and the foundation for designing artificial cells.
› Verified 4 days ago
Karl Hamouche, Radiology Medicare: Medicare Enrolled Practice Location: 551 N Hillside St Ste 320, Wichita, KS 67214 Phone: 316-685-1367 | |
Dr. Larry C Graham Ii, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3600 E Harry St, Wichita, KS 67218 Phone: 316-689-5050 Fax: 316-689-6192 | |
Tim Edward Stone, Radiology Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St, Wichita, KS 67214 Phone: 316-293-2665 | |
Dr. Donald C S Tan, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 817 N Emporia St, Via Christi Cancer Center, Wichita, KS 67214 Phone: 316-268-5927 | |
Elizabeth Perez-elmore, RN BSN Radiology Medicare: Not Enrolled in Medicare Practice Location: 5500 E Kellogg Dr, Wichita, KS 67218 Phone: 316-685-2221 | |
Mike Lam, DO Radiology Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St, Wichita, KS 67214 Phone: 316-293-2635 | |
Dr. Timothy C Benning, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3600 E Harry St, Wichita, KS 67218 Phone: 316-689-6173 |